Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06571162 · ClinicalTrials.gov registry record · NA
A Pragmatic INitiative for LDL-C Management by a CLinical Pharmacist-Led Team Among Atherosclerotic CardiovascUlar DisEase Patients
A NA study of Atherosclerotic Cardiovascular Disease, sponsored by Intermountain Health Care.
- Recruiting
- Registry status
- NA
- Development phase
- 400
- Enrollment target
- 1
- Study location
NCT06571162 is a NA study of Atherosclerotic Cardiovascular Disease that is actively recruiting participants, run by Intermountain Health Care. The registered enrollment target is 400 participants, below the 7,549-participant average among 21 other Atherosclerotic Cardiovascular Disease trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06571162, a NA study of Atherosclerotic Cardiovascular Disease, is actively recruiting participants, sponsored by Intermountain Health Care.
- RECRUITING
- Registry status
- NA
- Development phase
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients who had an ASCVD event at an Intermountain hospital will be screened for eligibility to be randomized. Subjects who meet eligibility criteria will be randomized 1:1 to receive targeted care of their LDL-C through a pharmacist-driven management program or not. Patients may opt-out of receiving LDL-C management by the pharmacy team at any time. The purpose of this program is to increase the proportion of patients who achieve guideline-based recommendations of LDL-C levels of \<70 mg/dL by increasing statin and/or LLT adherence and LDL-C testing. Data collection as part of the study will continue until the last person randomized has had 1-year of follow-up.
Conditions Studied
Interventions
- OTHER Usual Care
- OTHER Clinical Pharmacy Team
Study Locations (1)
Utah
- Intermountain Healthcare Hospitals and Clinics - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2025-01-30 |
| Est. Completion | 2028-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06571162
The ClinicalTrials.gov registry entry for NCT06571162 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 7,549-participant average among 21 other Atherosclerotic Cardiovascular Disease trials with a reported enrollment target (95% lower). The listed sponsor is Intermountain Health Care, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atherosclerotic Cardiovascular Disease appearing as the primary indexed condition, and to 2 interventions - of which Usual Care is the first listed.
NCT06571162 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT06571162 about?
NCT06571162 is a clinical study titled "A Pragmatic INitiative for LDL-C Management by a CLinical Pharmacist-Led Team Among Atherosclerotic CardiovascUlar DisEase Patients". Patients who had an ASCVD event at an Intermountain hospital will be screened for eligibility to be randomized. Subjects who meet eligibility criteria will be randomized 1:1 to receive targeted care of their LDL-C through a pharmacist-driven management program or not. Patients may opt-out of receivi...
What is the current status of trial NCT06571162?
This trial is currently recruiting. It is a NA study. The enrollment target is 400 participants. The study started on 2025-01-30. Estimated completion is 2028-09.
What conditions does trial NCT06571162 study?
This clinical trial studies the following conditions: Atherosclerotic Cardiovascular Disease.
What interventions are being tested in trial NCT06571162?
The interventions under investigation include: Usual Care (OTHER), Clinical Pharmacy Team (OTHER).
Who is sponsoring clinical trial NCT06571162?
This trial is sponsored by Intermountain Health Care, which has 85 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06571162 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerotic Cardiovascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Polygenic Risk Score Implementation and Stratification for Managing Blood Pressure
RECRUITING · NA
-
The Young Heart Study
ACTIVE NOT RECRUITING · NA
-
Behavioral Economic Approaches to Increase Physical Activity Among Patients With Elevated Risk for Cardiovascular Disease
COMPLETED · NA
-
A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)
COMPLETED · NA
-
Recipe for Heart Health
COMPLETED · NA
-
Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Immune Activation in Psoriasis
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.